Immunosuppressive Agents

"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Descriptor ID	D007166
MeSH Number(s)	D27.505.696.477.656
Concept/Terms	Immunosuppressive Agents Immunosuppressive Agents Agents, Immunosuppressive Immunosuppressants

Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Immunologic Factors [D27.505.696.477]
Immunosuppressive Agents [D27.505.696.477.656]

Below are MeSH descriptors whose meaning is related to "Immunosuppressive Agents".

Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.

Bar chart showing 318 publications over 31 distinct years, with a maximum of 18 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	4	1	5
1996	4	0	4
1997	7	4	11
1998	14	2	16
1999	9	7	16
2000	9	2	11
2001	7	5	12
2002	8	8	16
2003	6	8	14
2004	6	7	13
2005	11	1	12
2006	5	7	12
2007	4	5	9
2008	6	6	12
2009	11	7	18
2010	8	7	15
2011	7	5	12
2012	5	4	9
2013	5	4	9
2014	6	6	12
2015	6	11	17
2016	7	6	13
2017	6	8	14
2018	3	4	7
2019	3	1	4
2020	1	4	5
2021	2	5	7
2022	0	2	2
2023	1	4	5
2024	1	3	4
2025	1	1	2

Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.

Meister TL, Nocke MK, Heinen N, Burkard TL, Br?ggemann Y, Westhoven S, Tr?eb B, Ebert N, Thomann L, Lubieniecki KP, Lubieniecka JM, D?ring K, Herrmann M, Haid S, Pietschmann T, Wiegmann B, Tao R, Pfefferle S, Addo MM, Thiel V, Drexler I, Babel N, Phuc Nguyen H, Brown RJP, Todt D, Steinmann E, Pfaender S. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants. Proc Natl Acad Sci U S A. 2025 Jul 15; 122(28):e2500276122.

View in: PubMed
Anwar IJ, DeLaura I, Ladowski JM, Schilir? D, Gao Q, Manook M, Yoon J, Belloni R, Park A, Schuster DJ, Song M, Lin L, Farris AB, Magnani D, Williams K, Kwun J, Knechtle SJ. CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients. Sci Transl Med. 2025 Jan; 17(779):eadn8130.

View in: PubMed
Sangani R, Bosch NA, Govender P, Scarpato B, Walkey AJ, Newman J, Law AC, Gillmeyer KR, Shankar DA. Sarcoidosis Treatment Patterns in the United States: 2016-2022. Chest. 2025 Apr; 167(4):1099-1106.

View in: PubMed
D'Ambrosio ES, Allen MD, Ozes B, Sahenk Z. Concurrent nodular lymphocytic myositis and myasthenia gravis. A case report. Neuromuscul Disord. 2024 Dec; 45:105211.

View in: PubMed
L?pez-Medrano F, Carver PL, Rutjanawech S, Aranha-Camargo LF, Fernandes R, Belga S, Daniels SA, Mueller NJ, Burkhard S, Theodoropoulos NM, Postma DF, van Duijn PJ, Arnaiz de Las Revillas F, P?rez Del Molino-Bernal C, Hand J, Lowe A, Bodro M, Vanino E, Fern?ndez-Cruz A, Ramos-Mart?nez A, Makek MJ, Bou Mjahed R, Manuel O, Kamar N, Calvo-Cano A, Rueda-Carrasco L, Mu?oz P, ?lvarez-Ur?a A, P?rez-Recio S, Sab? N, Rodr?guez-?lvarez R, Silva JT, Mularoni A, Vidal E, Alonso-Titos J, Del Rosal T, Classen AY, Goss CW, Agarwal M, Mej?a-Chew C. Clinical Management and Outcomes of Nontuberculous Mycobacterial Infections in Solid Organ Transplant Recipients: A Multinational Case-control Study. Transplantation. 2025 02 01; 109(2):e134-e141.

View in: PubMed
Cao B, Robinson JE, Winget M, Hunt MH, Carlson R, Hogan SL, Derebail VK, Thorpe CT. Infection prophylaxis among patients with antineutrophil cytoplasmic antibody (ANCA) vasculitis: a scoping review. Clin Rheumatol. 2024 Sep; 43(9):2765-2781.

View in: PubMed
Massicotte-Azarniouch D, Detwiler RK, Hu Y, Falk RJ, Saha MK, van Duin D, Hogan SL, Derebail VK. Infections Following Kidney Transplantation After Exposure to Immunosuppression for Treatment of Glomerulonephritis. Am J Kidney Dis. 2024 06; 83(6):784-793.e1.

View in: PubMed
Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel JM, Wang J, Wheeler KE, Guyatt GH, Capozza K, Begolka WS, Chu AWL, Zhao IX, Chen L, Oykhman P, Bakaa L, Golden D, Shaker M, Bernstein JA, Greenhawt M, Horner CC, Lieberman J, Stukus D, Rank MA, Wang J, Ellis A, Abrams E, Ledford D, Chu DK. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024 03; 132(3):274-312.

View in: PubMed
DeLaura I, Zikos J, Anwar IJ, Yoon J, Ladowski J, Jackson A, Van Rompay K, Magnani D, Knechtle SJ, Kwun J. The impact of IdeS (imlifidase) on allo-specific, xeno-reactive, and protective antibodies in a sensitized rhesus macaque model. Xenotransplantation. 2024 Jan-Feb; 31(1):e12833.

View in: PubMed
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Coeck C, Schlecker C, Voss F, Wachtlin D, Martinez FJ. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res. 2023 09; 10(1).

View in: PubMed

People

Explore

Similar Concepts

Top Journals